Lipomas, Liposarcomas, and the Spectrum of Fatty Tumors: When the Lump Under Your Skin Matters — and When It Doesn't

Evidence Snapshot

• Lipoma is the most common soft-tissue tumor in adults. Lipomas account for approximately half of all soft-tissue tumors and most commonly present between ages 40 and 60 (Mentzel, 2001; Higgins et al., 2015; Salam, 2002)
• Metastatic potential of conventional lipoma: zero. Recurrence after complete excision: less than 1%.
• Metastatic potential of ALT/WDL: 0.1% in a systematic review of 793 patients (Choi et al., 2020)
• Local recurrence after marginal excision of superficial ALT/WDL: 8.4% at a median 54 months (Sivarajah et al., 2024). Expanded marginal excision: 100% 5-year local recurrence-free survival (Segu et al., 2025)
• MDM2/CDK4 amplification on chromosome 12q13-15 is the molecular fingerprint that separates ALT/WDL from a benign lipoma and is detectable by FISH or immunohistochemistry (Thway et al., 2012; Demicco, 2019)
• 2026 systemic therapy advances: Pembrolizumab added to neoadjuvant radiation and surgery raised 2-year disease-free survival from 52% to 67% in stage III soft-tissue sarcoma (Mowery et al., 2024). Afami-cel (MAGE-A4 TCR therapy) achieved a 25% response rate in heavily pretreated myxoid/round cell liposarcoma (D'Angelo et al., 2024)

What Is a Fatty Tumor?

Adipocytic tumors — the technical name for tumors of fat — are the most common soft-tissue tumors in the human body (Hameed, 2007; Mentzel, 2001). The vast majority are benign lipomas. The few that are not are among the most diagnostically interesting tumors in pathology, because some of them are nearly indistinguishable from a lipoma on first glance — and require molecular testing to reveal what they really are.

When a patient comes to my office with a lump under the skin, they almost always ask the same question: "Is this cancer?" The honest, statistical answer is "almost certainly not." The vast majority of soft, mobile, painless lumps that move under the fingertip are conventional lipomas. They are biologically lazy. They sit in the subcutaneous tissue. They do not invade. They do not spread. They do not become cancer.

The harder, more interesting question — and the one this article exists to answer — is: how do we know when a fatty lump is something else? That question is what separates a routine excision in a dermatology clinic from a referral to a specialized sarcoma center for advanced imaging, molecular testing, and a different kind of surgery.

The current World Health Organization (5th edition) classification of fatty tumors recognizes:

• Five common benign tumors: conventional lipoma, angiolipoma, spindle cell / pleomorphic lipoma, hibernoma, and lipoblastoma
• Two intermediate (locally aggressive) entities: atypical lipomatous tumor / well-differentiated liposarcoma (ALT/WDL), and its newer cousin atypical spindle cell / pleomorphic lipomatous tumor (ASPLT)
• Three malignant liposarcoma subtypes: dedifferentiated, myxoid/round cell, and pleomorphic (Creytens, 2020; Kallen & Hornick, 2021)

Dedifferentiated liposarcoma is the malignant progression of ALT/WDL — they share the same MDM2/CDK4 genetic signature, but DDL contains additional high-grade non-lipogenic components that change its clinical behavior dramatically.

Conventional Lipoma: The Quiet Cousin

A conventional lipoma is a benign tumor of mature fat cells (adipocytes), arranged in lobules, identical in appearance to the normal fat tissue surrounding them (Mentzel, 2001; Bean et al., 2018). The single most important fact about a lipoma is that it is biologically inert. The cells do not divide rapidly. They show no atypia. They display no mitotic figures. They sit, soft and mobile, in the subcutaneous tissue, and most of them never grow beyond a centimeter or two.

How a Pathologist Identifies a Lipoma

Under the microscope, lipomas show uniform mature fat cells with minimal variation in size and a thin fibrous capsule. On immunohistochemistry, adipocytes are positive for S100 protein but negative for MDM2 and CDK4 (Demicco, 2019; Thway et al., 2012). That last detail is the key distinction from ALT/WDL, which we will return to shortly.

The Genetic Fingerprint

Approximately 60–70% of cytogenetically abnormal lipomas show rearrangement of chromosome 12q13-15, with the HMGA2 gene being the most common target (Hameed, 2007; Mandahl et al., 1994). Less common alterations include 6p21-23 rearrangements and 13q deletions. These translocations drive cell growth but do not make the cells malignant — they are the genetic equivalent of pressing the gas pedal in a parked car with the parking brake engaged.

When to Treat and When to Leave Alone

For a small, soft, mobile, painless subcutaneous lump that has been stable for months, the appropriate management is observation. Lipomas do not have to be removed. They are not pre-cancerous. They will not turn into liposarcomas. The reasons to excise are practical: cosmetic concern, pain, interference with function, or any feature that makes me uncertain it is actually a lipoma.

Simple surgical excision is curative (Higgins et al., 2015; Shen-Wagner et al., 2024). Recurrence is exceedingly rare and essentially only occurs when the lipoma is incompletely removed.

The Rest of the Benign Family: Angiolipoma, Spindle Cell Lipoma, Hibernoma, Lipoblastoma

The remaining benign tumors share the fundamental biology of conventional lipoma — they do not metastasize — but each has features that change either how it presents or how it is treated.

Angiolipoma

Angiolipomas are distinguished clinically by two features that make them easy to recognize once you've seen one: they are often tender rather than painless, and patients frequently have multiple lesions, often appearing on the forearms or trunk in young adults (Mentzel, 2001; Drews-Elger & Williams, 2024). Histologically, mature fat cells are interspersed with networks of small thin-walled capillaries, sometimes containing fibrin thrombi. Simple excision is curative.

Spindle Cell and Pleomorphic Lipoma

Spindle cell and pleomorphic lipoma are now considered a single entity along a morphologic spectrum, unified by a single genetic signature: deletion of chromosome 13q14, including the RB1 gene (Demicco, 2019; Mariño-Enriquez et al., 2017). Classically, this tumor presents as a slow-growing painless mass on the posterior neck, shoulder, or upper back of an older man, though cutaneous variants are more common in women and have a broader anatomic distribution.

Histologically, you see a mixture of mature fat, bland spindle cells, ropey collagen, and occasional "floret" giant cells with rosette-like nuclei. The spindle cells stain for CD34 in about two-thirds of cases and may show variable S100 and desmin expression (Mariño-Enriquez et al., 2017; Lecoutere & Creytens, 2020). Recurrence is low after local excision, and metastasis does not occur.

Hibernoma

The hibernoma is the rarest and most picturesque of the benign tumors — composed of multivacuolated brown fat-like cells that resemble the thermogenic tissue used by hibernating mammals to keep warm. The defining alteration is a structural rearrangement of chromosome 11q13, often involving the MEN1 locus (Kojima et al., 2022). Hibernomas show strong S100 positivity and complete excision is curative.

Here is the diagnostic trap worth knowing: liposarcomas — particularly well-differentiated and myxoid subtypes — can occasionally take on hibernoma-like histology, with multivacuolated cells and even UCP1 expression. When in doubt, MDM2/CDK4 testing or DDIT3 testing distinguishes a true hibernoma from a hibernoma-mimic liposarcoma (Kojima et al., 2022).

Lipoblastoma

Lipoblastoma is a pediatric tumor — almost exclusively diagnosed in children under three years of age. It is defined by rearrangement of chromosome 8q11-13, most commonly involving the PLAG1 gene (Putra & Al-Ibraheemi, 2019). Complete surgical excision is curative; the only meaningful risk is local recurrence if the tumor is incompletely removed.

ALT/WDL: The Look-Alike That Demands Respect

If there is one entity on this entire list that I want every patient and every clinician to understand, it is atypical lipomatous tumor / well-differentiated liposarcoma (ALT/WDL). The name itself is informative: it is called atypical lipomatous tumor when it is in a location where it can be completely removed (limb, trunk, skin), and well-differentiated liposarcoma when it is in a location where it cannot (retroperitoneum). The biology is identical. The only thing that changes is the surgical accessibility — and therefore the long-term consequences.

The Defining Genetic Lesion

ALT/WDL is defined by amplification of the 12q13-15 chromosomal region, which contains the MDM2 and CDK4 genes (Hameed, 2007; Sirvent et al., 2007). This amplification typically appears as supernumerary ring chromosomes or giant rod chromosomes — abnormal structures visible on classical cytogenetics. It is the gold-standard diagnostic finding, detectable by fluorescence in situ hybridization (FISH) or by immunohistochemistry for MDM2 and CDK4 nuclear positivity.

Importantly, MDM2/CDK4 amplification is absent in conventional lipomas, in spindle cell/pleomorphic lipomas, and in the newly recognized atypical spindle cell/pleomorphic lipomatous tumor. The presence or absence of this amplification is what separates a benign lipoma from a tumor that can recur and (rarely) progress.

What It Looks Like Under the Microscope

Histologically, ALT/WDL shows mature adipocytes with conspicuous variation in cell size, hyperchromatic stromal cells (cells with dark, irregular nuclei in the fibrous strands between fat lobules), and occasional lipoblasts (immature fat cells with characteristic indentations of the nucleus by lipid vacuoles). The maximum range of adipocyte size is significantly greater than in benign lipoma — a quantifiable feature that digital pathology has helped formalize (Bean et al., 2018).

Immunohistochemistry adds critical confirmation. The combination of MDM2, CDK4, and p16 achieves a sensitivity of 71% and specificity of 98% for ALT/WDL (Thway et al., 2012). p16 alone is the most sensitive single marker (sensitivity 93%, specificity 92%) — a useful piece of practical knowledge for any pathologist working through a deceptive fatty tumor.

The Clay Criteria: Knowing When to Test

Not every well-differentiated fatty tumor needs MDM2 FISH testing. The Clay criteria — originally articulated by Clay and colleagues at Emory University in 2016 (Clay et al., 2016) and recently validated in a large retrospective utilization review of 1,151 cases by Flaman and colleagues at Toronto's Mount Sinai Hospital (Flaman et al., 2025) — define when molecular testing is most cost-effective and clinically necessary. The four criteria are:

1. Location: retroperitoneum, abdomen, or pelvis
2. Size: greater than 10 cm
3. Age: patient over 50 years old
4. Histology: presence of nuclear atypia

When these criteria are combined with nuclear atypia on histology, sensitivity for ALT/WDL approaches 97.8%. The practical implication: small, superficial, classic-appearing lipomas in younger patients do not require expensive molecular workup.

How ALT/WDL Behaves Clinically

The tumor is locally aggressive but essentially never lethal when arising in a superficial location. In a large retrospective study from a specialist sarcoma center, Sivarajah and colleagues reported a local recurrence rate of 8.4% at a median 54-month follow-up after marginal excision, with an extremely low rate of distant relapse and zero disease-related deaths (Sivarajah et al., 2024).

A systematic review of 793 patients found marginal excision associated with an 11.9% local recurrence rate versus 3.3% for wide excision (Choi et al., 2020). But — and this is the teaching point — recurrences were almost always amenable to re-resection. Dedifferentiation occurred in only 1.1% of cases. Metastasis occurred in 0.1%. Put differently: for the average patient with a superficial ALT/WDL, the long-term risk of dying from the tumor is approximately one in a thousand.

More recently, Segu and colleagues demonstrated that expanded marginal excision — removal of all tissue infiltrated by fat, including fascia or muscle if involved — achieved 100% five-year local recurrence-free survival in a 105-patient cohort, comparable to traditional wide resection (Segu et al., 2025). There is no established role for adjuvant radiotherapy or chemotherapy following complete excision of superficial ALT/WDL.

Atypical Spindle Cell / Pleomorphic Lipomatous Tumor (ASPLT)

A newer entity, formally recognized in the fifth edition WHO classification, is the atypical spindle cell / pleomorphic lipomatous tumor (ASPLT) (Creytens, 2020; Nishio et al., 2024). It is defined genetically by what it lacks: no MDM2/CDK4 amplification. It is defined by what it has: frequent RB1 deletion on chromosome 13q14.

Histologically, ASPLT contains a mixture of atypical spindle cells, adipocytes, lipoblasts, and pleomorphic cells. Immunohistochemistry shows variable CD34, S100, and desmin expression, with loss of nuclear Rb in most cases (Lecoutere & Creytens, 2020; Anderson et al., 2021). Local recurrence occurs in 4–13% of cases — but metastasis has not been observed. Complete surgical excision remains the treatment of choice.

The Three Malignant Liposarcomas

The three malignant liposarcomas — dedifferentiated, myxoid/round cell, and pleomorphic — are uncommon tumors that together account for fewer than one in a hundred fatty tumors. They are usually deep rather than cutaneous. But they are the entities that justify the entire molecular diagnostic apparatus, because the consequences of missing them or under-treating them are real.

Dedifferentiated Liposarcoma (DDL)

Dedifferentiated liposarcoma shares the MDM2/CDK4 amplification of ALT/WDL but is biologically distinct: it contains areas of non-lipogenic, often high-grade sarcoma in addition to the well-differentiated component. The tumor can arise either de novo or by progression from an existing ALT/WDL — typically over years.

Local recurrence is high, and metastatic rates range from 15–30% (Creytens, 2020; De Vita et al., 2016; Mendoza-Moreno et al., 2023). The standard treatment is wide surgical excision with negative margins, with adjuvant radiotherapy considered for close or positive margins (Le Nail et al., 2022).

A useful clinical pearl: superficial DDL is rare but real, and when it arises primarily in the skin or subcutaneous tissue (rather than as secondary cutaneous involvement from a deeper tumor), the prognosis is dramatically better. Bourgeau and colleagues studied 14 cases of superficial DDL and found that all patients with primary superficial disease were disease-free at last follow-up after re-excision and radiation when indicated (Bourgeau et al., 2024).

Myxoid / Round Cell Liposarcoma

Myxoid/round cell liposarcoma is genetically the most elegant tumor in this group, defined by a single recurrent translocation: t(12;16)(q13;p11), generating the FUS-DDIT3 fusion gene — or, less commonly, EWSR1-DDIT3 (Hameed, 2007; Creytens, 2019). Histologically, it features a prominent myxoid (mucinous-appearing) stroma, arborizing capillaries, and lipoblasts. The tumor has a characteristic location preference for the thigh in young to middle-aged adults.

The prognosis depends heavily on the round cell content. Pure myxoid tumors have favorable five-year survival; tumors with significant round cell areas behave much more aggressively. Treatment is wide excision plus adjuvant radiotherapy, taking advantage of the relative radiosensitivity of this subtype (Le Nail et al., 2022; De Vita et al., 2016).

The exciting development in this disease is trabectedin — a marine-derived tetrahydroisoquinoline alkaloid that binds the minor groove of DNA and overcomes the differentiation block created by the FUS-DDIT3 fusion. Sanfilippo and colleagues published a JAMA Oncology study in 2023 evaluating trabectedin plus radiotherapy in 41 patients with myxoid liposarcoma, demonstrating a 22% partial response rate by central RECIST review (9/41) with durable disease control, though the trial did not meet its primary endpoint of RECIST response in ≥70% of patients (Sanfilippo et al., 2023). Separately, Gronchi and colleagues later demonstrated in an Italian–Spanish–French–Polish randomized trial that neoadjuvant trabectedin was non-inferior to standard anthracycline/ifosfamide for high-grade myxoid liposarcoma of the extremities or trunk, with 60-month disease-free survival of 86% versus 73% favoring trabectedin (Gronchi et al., 2024; Lee & von Mehren, 2024).

Pleomorphic Liposarcoma

Pleomorphic liposarcoma is the rarest and most aggressive of the three malignant liposarcomas. Unlike the others, it has no recurrent genetic signature — its karyotype is complex and chaotic, with widespread chromosomal disruption rather than a single defining alteration (Demicco, 2019; Creytens, 2020).

Clinical behavior reflects the genetics. Recurrence rates exceed 30–50%, metastatic rates are similarly high, and five-year survival is reported as low as 30–50% (De Vita et al., 2016; Mendoza-Moreno et al., 2023). Aggressive surgical management with wide margins is required, and adjuvant radiotherapy is commonly recommended.

Comparison Table: Every Adipocytic Tumor at a Glance

Sources: Hameed, 2007; Mentzel, 2001; Creytens, 2020; Demicco, 2019; Thway et al., 2012; Sivarajah et al., 2024; Choi et al., 2020; Segu et al., 2025; De Vita et al., 2016; Sanfilippo et al., 2023

How a Suspicious Fatty Tumor Should Be Worked Up

The European expert consensus on adipocytic soft-tissue tumors offers the clearest practical framework for what to do when a fatty mass is more concerning than a routine lipoma (Moulin et al., 2022; Lepage et al., 2023). The recommendation is a tiered, algorithmic approach that escalates testing in proportion to suspicion.

Step 1: Clinical Examination and Imaging

For any soft-tissue mass that is deep, larger than 3 cm, rapidly growing, painful, or arising in a high-risk anatomic site (retroperitoneum, abdomen, pelvis, or the proximal extremities of a patient over 50), the workup begins with MRI. MRI can identify features that strongly suggest an atypical or malignant tumor — septations thicker than 2 mm, non-fatty components, enhancement after contrast, and the absence of a clean fat-only signal.

Step 2: Core Needle Biopsy

For lesions that imaging cannot definitively classify, image-guided core needle biopsy is the appropriate next step. Thavikulwat and colleagues at Boston University reported that core needle biopsy achieves 100% diagnostic concordance with surgical pathology for benign lipomas and for high-grade liposarcomas (Thavikulwat et al., 2021). The concordance for ALT/WDL is lower — only 81% — because of the sampling problem inherent in heterogeneous fatty tumors.

Step 3: Immunohistochemistry and Molecular Testing

If histology raises any suspicion, the next layer is immunohistochemistry. The standard triple panel for ALT/WDL is MDM2, CDK4, and p16 — sensitivity 71%, specificity 98% in combination (Thway et al., 2012). If a spindle cell or pleomorphic component is present, Rb (RB1) staining helps distinguish spindle cell/pleomorphic lipoma and ASPLT (Rb-lost) from ALT/WDL (Rb-retained) (Dry, 2025; Kilpatrick, 2024).

When immunohistochemistry is ambiguous, FISH for MDM2 amplification is the gold-standard tiebreaker (Sirvent et al., 2007; Zhang et al., 2010). For myxoid liposarcoma, FISH, RT-PCR, or next-generation sequencing for the FUS-DDIT3 or EWSR1-DDIT3 fusion is definitive (Creytens, 2019; Serrano et al., 2025).

Emerging Tools

Two developments worth following:

• Radiomics and deep-learning MRI: A multi-center external validation study in EClinicalMedicine demonstrated that automated radiomics and deep-learning models can differentiate ALT/WDL from benign lipoma with an AUC of 0.74–0.89 — performance comparable to expert musculoskeletal radiologists (Spaanderman et al., 2024).
• Magnetic resonance spectroscopy: High-resolution MRS at 17.6T has shown distinct metabolic signatures separating benign lipoma, ALT/WDL, and dedifferentiated liposarcoma, though this technology remains experimental (Bharti et al., 2022).

What's New in 2024–2026: Targeted and Immunologic Therapy

For patients with malignant liposarcomas — the small minority of fatty tumors that fall into the dedifferentiated, myxoid/round cell, or pleomorphic categories — the last two years have brought more genuine therapeutic advances than the prior two decades combined.

CDK4 inhibitors — abemaciclib and palbociclib — have shown clinical activity in phase 2 trials of dedifferentiated liposarcoma, with 12-week progression-free survival rates of 74% and 57% respectively. The phase 3 SARC041 trial (NCT04967521) is currently evaluating abemaciclib versus placebo in advanced DDL (Lee & von Mehren, 2024; Franza et al., 2024; Dickson et al., 2023).

MDM2 inhibitors — milademetan and brigimadlin (BI907828) — restore p53-driven tumor suppression in MDM2-amplified liposarcoma. Late-stage pivotal studies are ongoing (Lesovaya et al., 2024).

Selinexor, an exportin-1 (XPO1) inhibitor, has demonstrated single-agent activity in DDL (Li & Chen, 2023). And in a phase 2 EORTC study, cabazitaxel achieved a median progression-free survival of 6.5 months and a disease control rate of 68% in metastatic or inoperable DDL (Sanfilippo et al., 2022).

The most clinically practice-changing study in soft-tissue sarcoma in years is SU2C-SARC032, published in The Lancet in 2024 (Mowery et al., 2024). In a randomized open-label trial of patients with stage III undifferentiated pleomorphic sarcoma or dedifferentiated/pleomorphic liposarcoma of the extremity and limb girdle, the addition of pembrolizumab to neoadjuvant radiotherapy and surgery improved 2-year disease-free survival from 52% to 67% — a statistically significant 15-point absolute benefit.

The most futuristic therapy on this list is engineered T-cell receptor (TCR) therapy targeting MAGE-A4. In the SPEARHEAD-1 phase 2 trial, afamitresgene autoleucel (afami-cel, marketed as TECELRA) achieved an overall response rate of 25% in heavily pretreated patients with myxoid round cell liposarcoma (D'Angelo et al., 2024). The therapy is restricted to patients with HLA-A*02 alleles and MAGE-A4 expression. Afami-cel received FDA approval in August 2024 for advanced synovial sarcoma based on the SPEARHEAD-1 synovial cohort; for myxoid/round cell liposarcoma it remains investigational, but the SPEARHEAD-1 data represent the first signal of meaningful activity for an engineered TCR therapy in any liposarcoma.

A consensus review by Serrano and colleagues in JAMA Oncology summarized the genetic and genomic alterations across sarcoma subtypes and the drugs with regulatory approval for each — a practical reference for any clinician guiding a sarcoma patient through 2026's expanding therapeutic landscape.

When to See a Specialist

For most patients with a soft lump under the skin, the appropriate first stop is a dermatologist or primary care physician. The features that should prompt earlier or more aggressive referral — ideally to a center with sarcoma expertise — are summarized below.

The single best predictor of an excellent outcome with any soft-tissue sarcoma is getting to the right center before the first surgery. A poorly planned initial excision — a "shell-out" of what was assumed to be a benign lipoma — is the most common cause of unnecessary second operations, larger eventual resections, and worse long-term outcomes (Moulin et al., 2022; Sivarajah et al., 2024).

Frequently Asked Questions

1. Will my lipoma ever turn into cancer?

No. Conventional lipomas — the soft, mobile, painless lumps that most people develop — do not transform into liposarcoma. The genetics are different, the biology is different, and there is no epidemiologic evidence that a benign lipoma evolves into a malignant tumor. The concern is not that a lipoma "becomes" cancer; the concern is that a tumor that looked like a lipoma from the start turns out, on pathology, to have been something else (most commonly ALT/WDL).

2. How can I tell at home whether my lump is just a lipoma?

Reassuring features are small (under 5 cm), soft, mobile under the fingertip, painless, stable in size for months, and located in the subcutaneous fat of the trunk, arms, or legs in a patient under 50. Concerning features are rapid growth, pain, fixation to deeper tissues, size greater than 5 cm, location in the retroperitoneum or proximal thigh, and any new mass in a patient over 50. If your lump has any concerning features, see a dermatologist or surgeon for evaluation — and ideally imaging — before any procedure.

3. Does every lipoma need to be removed?

No. For a small, soft, mobile, painless, stable lump that has been present for months or years without change, observation is entirely appropriate. Reasons to remove a lipoma include cosmetic concern, pain, interference with function, rapid growth, or any diagnostic uncertainty.

4. What is the difference between a lipoma and an atypical lipomatous tumor?

Visually, they can be indistinguishable. The difference lies at the molecular level: ALT/WDL has amplification of MDM2 and CDK4 on chromosome 12, which a conventional lipoma does not have. This amplification is detected either by immunohistochemistry (MDM2 and CDK4 nuclear staining) or by fluorescence in situ hybridization (FISH). Clinically, ALT/WDL is more likely to be large, deep, in older patients, and in high-risk anatomic locations (Flaman et al., 2025; Clay et al., 2016).

5. Is well-differentiated liposarcoma a deadly cancer?

Not when it arises in the skin, trunk, or extremity. Cutaneous and superficial ALT/WDL has a metastatic risk of approximately 0.1% and no disease-related deaths in large modern series (Sivarajah et al., 2024; Choi et al., 2020). When the same biology arises in the retroperitoneum, the prognosis is much worse — not because the cells are more aggressive, but because the retroperitoneum cannot be completely cleared surgically.

6. What kind of surgery is best for an atypical lipomatous tumor on the trunk or extremity?

The current best evidence supports expanded marginal excision — removing all tissue infiltrated by fat, including fascia or muscle if involved. This approach achieved 100% five-year local recurrence-free survival in a 2025 cohort study, comparable to traditional wide resection but with less morbidity (Segu et al., 2025). Simple marginal "shell-out" excision has a local recurrence rate of 8–12%, while wide resection has a recurrence rate near 3% (Choi et al., 2020; Sivarajah et al., 2024). Adjuvant radiation or chemotherapy is not recommended for completely excised superficial ALT/WDL.

7. Should I see a sarcoma specialist before my biopsy?

For any soft-tissue mass that is deep, larger than 5 cm, rapidly growing, or located in the retroperitoneum, abdomen, pelvis, or proximal thigh — yes. The European expert consensus, the National Comprehensive Cancer Network guidelines, and every modern sarcoma reference agree on this point (Moulin et al., 2022; Lepage et al., 2023).

8. What are the new drugs for liposarcoma?

For dedifferentiated liposarcoma, the most promising agents are CDK4 inhibitors (abemaciclib, palbociclib), MDM2 inhibitors (milademetan, brigimadlin), selinexor, and cabazitaxel (Lee & von Mehren, 2024; Sanfilippo et al., 2022; Dickson et al., 2023). For myxoid/round cell liposarcoma, the leading targeted agents are trabectedin — non-inferior to standard anthracycline/ifosfamide for neoadjuvant therapy (Gronchi et al., 2024) and active in combination with radiation (Sanfilippo et al., 2023) — and the engineered T-cell receptor therapy afami-cel in HLA-A*02 patients with MAGE-A4-expressing tumors (D'Angelo et al., 2024). For resectable high-grade dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdle, adding pembrolizumab to neoadjuvant radiation and surgery improved 2-year disease-free survival from 52% to 67% in the SU2C-SARC032 trial (Mowery et al., 2024).

9. Are children with fatty tumors evaluated differently?

Yes. The most common pediatric adipocytic tumor is lipoblastoma, defined by PLAG1 rearrangement on chromosome 8q11-13 (Putra & Al-Ibraheemi, 2019). It is benign, with complete surgical excision being curative. Liposarcomas are exceptionally rare in children.

10. What follow-up do I need after surgery for an atypical lipomatous tumor?

Current evidence supports clinical examination every 6–12 months for at least 5 years following complete excision of cutaneous or superficial ALT/WDL (Sivarajah et al., 2024; Choi et al., 2022). Imaging surveillance (MRI) is considered for deeper or larger tumors. Late recurrences beyond 10 years have been reported, so most experts recommend ongoing periodic surveillance even after the five-year mark.

Related Reading on Skin Trust

• Understanding Your Pathology Report — How to read a dermatopathology report, what terms like "margin status," "atypia," and "mitotic rate" mean.
• The Complete Guide to Surgical Scars — What to expect after a lipoma excision, including realistic scar expectations.
• How to Choose the Best Mohs Surgeon — Many of the same principles for choosing a high-volume, fellowship-trained specialist apply to choosing a soft-tissue surgeon for an atypical fatty tumor.

References

Hameed M. Pathology and Genetics of Adipocytic Tumors. Cytogenetic and Genome Research. 2007;118(2-4):138-147. PMID: 18000364

Mentzel T. Cutaneous Lipomatous Neoplasms. Seminars in Diagnostic Pathology. 2001;18(4):250-257. PMID: 11757864

Creytens D. What's New in Adipocytic Neoplasia? Virchows Archiv. 2020;476(1):29-39. PMID: 31501988

Kilpatrick SE. Atypical Lipomatous Tumor/Well Differentiated Liposarcoma and Related Mimics With Updates. Human Pathology. 2024;147:82-91. PMID: 38135062

Kallen ME, Hornick JL. The 2020 WHO Classification: What's New in Soft Tissue Tumor Pathology? The American Journal of Surgical Pathology. 2021;45(1):e1-e23. PMID: 32796172

Demicco EG. Molecular Updates in Adipocytic Neoplasms. Seminars in Diagnostic Pathology. 2019;36(2):85-94. PMID: 30857767

Serrano C, Bauer S, Blay JY, et al. Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment. JAMA Oncology. 2025;11(12):1527-1537. doi:10.1001/jamaoncol.2025.3608.

Higgins JC, Maher MH, Douglas MS. Diagnosing Common Benign Skin Tumors. American Family Physician. 2015;92(7):601-607. PMID: 26447443

Salam GA. Lipoma Excision. American Family Physician. 2002;65(5):901-904. PMID: 11898962

Bean GR, Wen KW, Horvai AE. Adipocyte Size Variability in Benign and Malignant Lipomatous Tumors. Human Pathology. 2018;72:52-58. PMID: 29128479

Thway K, Flora R, Shah C, Olmos D, Fisher C. Diagnostic Utility of P16, CDK4, and MDM2 as an Immunohistochemical Panel. The American Journal of Surgical Pathology. 2012;36(3):462-469. PMID: 22301498

Mandahl N, Höglund M, Mertens F, et al. Cytogenetic Aberrations in 188 Benign and Borderline Adipose Tissue Tumors. Genes, Chromosomes & Cancer. 1994;9(3):207-215. PMID: 7515663

Shen-Wagner J, Amidon J, Carek S. Diagnosing Common Benign Skin Tumors. American Family Physician. 2024;110(4):353-361. PMID: 39418568

Drews-Elger K, Williams EA. Mesenchymal Tumors of the Skin: A Review. Advances in Anatomic Pathology. 2024;31(6):442-450. PMID: 39466699

Mariño-Enriquez A, Nascimento AF, Ligon AH, Liang C, Fletcher CD. Atypical Spindle Cell Lipomatous Tumor: Clinicopathologic Characterization of 232 Cases. The American Journal of Surgical Pathology. 2017;41(2):234-244. PMID: 27879515

Lecoutere E, Creytens D. Atypical Spindle Cell/Pleomorphic Lipomatous Tumor. Histology and Histopathology. 2020;35(8):769-778. PMID: 32068239

Kojima N, Komiyama M, Shinoda Y, et al. Liposarcoma With Hibernoma-Like Histology. The American Journal of Surgical Pathology. 2022;46(10):1319-1328. PMID: 35475774

Putra J, Al-Ibraheemi A. Adipocytic Tumors in Children: A Contemporary Review. Seminars in Diagnostic Pathology. 2019;36(2):95-104. PMID: 30850231

Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 Amplification by FISH in 200 Paraffin-Embedded Tumor Samples. The American Journal of Surgical Pathology. 2007;31(10):1476-1489. PMID: 17895748

Clay MR, Martinez AP, Weiss SW, Edgar MA. MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors? A New Perspective. The American Journal of Surgical Pathology. 2016;40(12):1647-1652. PMID: 27508976

Flaman AN, Zhang L, Dickson BC, Demicco EG. Criteria for MDM2 Fluorescence in Situ Hybridization Testing in the Diagnosis of Well-Differentiated Adipocytic Neoplasms. Virchows Archiv. 2025;487(6):1279-1289. PMID: 41269286

Sivarajah G, Snow H, Wilkinson MJ, et al. Low Local Recurrence Rates Following Marginal Surgical Resection of Non-Coelomic ALT/WDL. European Journal of Surgical Oncology. 2024;50(1):107301. PMID: 38041960

Choi KY, Jost E, Mack L, Bouchard-Fortier A. Surgical Management of Truncal and Extremities ALT/WDL: A Systematic Review. American Journal of Surgery. 2020;219(5):823-827. PMID: 32029218

Segu HV, Rampam S, Gonzalez MR, et al. Comparison of Local Recurrence Rates Between Wide Resection and Expanded Marginal Excision in ALT. Annals of Surgical Oncology. 2025. PMID: 40490638

Choi KY, Mack L, Caragea M, et al. MDM2 Analysis in the Management of Benign Lipomas Versus ALT/WDL. American Journal of Surgery. 2022;224(2):747-750. PMID: 35397923

Nishio J, Nakayama S, Chijiiwa Y, Koga M, Aoki M. Atypical Spindle Cell/Pleomorphic Lipomatous Tumor: A Review and Update. Cancers. 2024;16(18):3146. PMID: 39335118

Anderson WJ, Fletcher CDM, Jo VY. Atypical Pleomorphic Lipomatous Tumor: Clinicopathologic Analysis of 64 Cases. The American Journal of Surgical Pathology. 2021;45(9):1282-1292. PMID: 33782225

De Vita A, Mercatali L, Recine F, et al. Current Classification, Treatment Options, and New Perspectives in the Management of Adipocytic Sarcomas. OncoTargets and Therapy. 2016;9:6233-6246. PMID: 27785071

Mendoza-Moreno F, Matías-García B, Quiroga-Valcárcel A, et al. Malignant Adipocytic Tumours: A 20-year Single-centre Retrospective Study. Oncology Letters. 2023;25(6):247. PMID: 37153046

Le Nail LR, Crenn V, Rosset P, Ropars M. Management of Adipose Tumors in the Limbs. Orthopaedics & Traumatology, Surgery & Research. 2022;108(1S):103162. PMID: 34863958

Bourgeau M, Gandhi JS, Deeb KK, Bahrami A. Superficial Dedifferentiated Liposarcoma: A Clinicopathologic Study. Human Pathology. 2024;145:63-70. PMID: 38423223

Creytens D. A Contemporary Review of Myxoid Adipocytic Tumors. Seminars in Diagnostic Pathology. 2019;36(2):129-141. PMID: 30853315

Sanfilippo R, Hindi N, Cruz Jurado J, et al. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma. JAMA Oncology. 2023;9(5):656-663. doi:10.1001/jamaoncol.2023.0056.

Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial. Journal of Clinical Oncology. 2024;42(8):898-906. PMID: 38232337

Lee TY, von Mehren M. Novel Pharmacotherapies for the Treatment of Liposarcoma. Expert Opinion on Pharmacotherapy. 2024;25(17):2293-2306. PMID: 39535168

Franza A, Fabbroni C, Pasquali S, Casali PG, Sanfilippo R. New Targeted Therapies in Liposarcoma. Current Opinion in Oncology. 2024;36(4):291-296. PMID: 38726840

Moulin B, Messiou C, Crombe A, et al. Diagnosis Strategy of Adipocytic Soft-Tissue Tumors in Adults: European Expert Consensus. European Journal of Surgical Oncology. 2022;48(3):518-525. PMID: 34688512

Lepage B, Ropars M, Crepin V, et al. The Value of a New Diagnostic Strategy for Adipocytic Soft Tissue Tumors. European Journal of Surgical Oncology. 2023;49(10):107012. PMID: 37572589

Thavikulwat AC, Wu JS, Chen X, et al. Image-Guided Core Needle Biopsy of Adipocytic Tumors. AJR American Journal of Roentgenology. 2021;216(4):997-1002. PMID: 33624523

Dry S. Updates in Peripheral Nerve Sheath and Adipocytic Tumors. Modern Pathology. 2025;39(1):100929. PMID: 41183597

Zhang H, Erickson-Johnson M, Wang X, et al. Molecular Testing for Lipomatous Tumors. The American Journal of Surgical Pathology. 2010;34(9):1304-1311. PMID: 20679883

Spaanderman DJ, Hakkesteegt SN, Hanff DF, et al. Multi-Center External Validation of Radiomics and Deep-Learning on MRI for ALT vs Lipoma. EClinicalMedicine. 2024;76:102802. PMID: 39351025

Bharti SK, Shannon BA, Sharma RK, et al. Characterization of Lipomatous Tumors With High-Resolution H MRS at 17.6T. Frontiers in Oncology. 2022;12:920560. PMID: 36158671

Dickson M, Ballman K, Weiss M, et al. SARC041: A Phase 3 Study of Abemaciclib vs Placebo in Advanced DDL. Journal of Clinical Oncology. 2023;41(Suppl 16):TPS11587.

Lesovaya EA, Fetisov TI, Bokhyan BY, et al. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma. Cancers. 2024;16(2):271. PMID: 38254762

Li CC, Chen TW. New Targeted Treatments for Advanced Sarcomas. Current Opinion in Oncology. 2023;35(4):309-314. PMID: 37222206

Sanfilippo R, Hayward RL, Musoro J, et al. Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced DDL: EORTC Phase 2 Study. JAMA Oncology. 2022;8(10):1420-1425. doi:10.1001/jamaoncol.2022.3218.

Mowery YM, Ballman KV, Hong AM, et al. Pembrolizumab + RT + Surgery vs RT + Surgery for Stage III Soft Tissue Sarcoma (SU2C-SARC032). Lancet. 2024;404(10467):2053-2064. PMID: 39547252

D'Angelo SP, Araujo DM, Abdul Razak AR, et al. Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma (SPEARHEAD-1). Lancet. 2024;403(10435):1460-1471. PMID: 38554725